How Novo Nordisk’s Missed Patent Fee In Canada May Cost Billions — And What It Means For Your IP Strategy
How Novo Nordisk’s Missed Patent Fee In Canada May Cost Billions — And What It Means For Your IP Strategy In a cautionary tale for innovators and pharmaceutical giants alike,…